Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 2/2020

01-04-2020 | Research Article

Medication exposure and frailty in older community-dwelling patients: a cross-sectional study

Authors: Elsa Reallon, Bénédicte Chavent, Frédéric Gervais, Virginie Dauphinot, Julien Vernaudon, Pierre Krolak-Salmon, Christelle Mouchoux, Teddy Novais

Published in: International Journal of Clinical Pharmacy | Issue 2/2020

Login to get access

Abstract

Objective To investigate the association between the medication exposure, measured by the polypharmacy/excessive polypharmacy and the anticholinergic and/or sedative drug exposure, on frailty status among French older community-dwelling patients. Setting day-care unit in France (Lyon), with retrospective data from July, 2017 to March, 2018. Method This monocentric cross-sectional study included community-dwelling patients aged 65 years and over and admitted at the day-care unit for a geriatric evaluation. Frailty was assessed according to the frailty phenotype, described by Fried et al. Polypharmacy and excessive polypharmacy were defined as the concomitant use of 5–9 and 10 or more drugs, respectively. The cumulative anticholinergic and sedative exposure was measured using the drug burden index (DBI). The DBI score was presented in 4 differentiated scores: a null score (DBI = 0), a combined score (anticholinergic and sedative score), an anticholinergic score, and a sedative score. The association between medication and frailty was assessed by logistic regression models controlled for multiple potential confounders. Main outcome measure Association between medication exposure (polypharmacy, anticholinergic and sedative exposure) and frailty. Results In this study, 403 patients were included: 44.7% were frail and 40.7% were pre-frail. Polypharmacy and excessive polypharmacy affected 44.7% and 17.1% of the population respectively. The mean DBI was 0.33 ± 0.43, with 16.4% of patients with only sedative exposure, 9.7% with only anticholinergic exposure and 33.0% with both exposures. After adjustment, polypharmacy and excessive polypharmacy were associated with frailty with adjusted odds ratios (95% confidence interval) of 2.18 (1.03–4.22) and 2.72 (1.01–7.37) respectively. The cumulative exposure to anticholinergic and sedative drugs (combined score) was significantly associated to an increased risk for frailty with adjusted odds ratios (95% confidence interval) of 3.54 (1.47–8.57). Conclusion The study showed that polypharmacy and cumulative anticholinergic and sedative exposure are associated with frailty. Further research should address the potential benefit of collaborative medication review for preventing medication-associated frailty.
Literature
1.
go back to reference Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol Ser A Biol Sci Med Sci. 2001;56(3):M146–156.CrossRef Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol Ser A Biol Sci Med Sci. 2001;56(3):M146–156.CrossRef
2.
go back to reference Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet Lond Engl. 2013;381(9868):752–62.CrossRef Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet Lond Engl. 2013;381(9868):752–62.CrossRef
3.
go back to reference Song X, Mitnitski A, Rockwood K. Prevalence and 10-year outcomes of frailty in older adults in relation to deficit accumulation. J Am Geriatr Soc. 2010;58(4):681–7.PubMedCrossRef Song X, Mitnitski A, Rockwood K. Prevalence and 10-year outcomes of frailty in older adults in relation to deficit accumulation. J Am Geriatr Soc. 2010;58(4):681–7.PubMedCrossRef
4.
go back to reference Eeles EMP, White SV, O’Mahony SM, Bayer AJ, Hubbard RE. The impact of frailty and delirium on mortality in older inpatients. Age Ageing. 2012;41(3):412–6.PubMedCrossRef Eeles EMP, White SV, O’Mahony SM, Bayer AJ, Hubbard RE. The impact of frailty and delirium on mortality in older inpatients. Age Ageing. 2012;41(3):412–6.PubMedCrossRef
5.
go back to reference Mangerel K, Armand-Branger S, Rhalimi M. Spécificités de la personne âgée et leurs conséquences sur la prise en charge médicamenteuse. 2011;30:167–73. Mangerel K, Armand-Branger S, Rhalimi M. Spécificités de la personne âgée et leurs conséquences sur la prise en charge médicamenteuse. 2011;30:167–73.
6.
go back to reference Field TS, Gurwitz JH, Avorn J, McCormick D, Jain S, Eckler M, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med. 2001;161(13):1629–34.CrossRefPubMed Field TS, Gurwitz JH, Avorn J, McCormick D, Jain S, Eckler M, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med. 2001;161(13):1629–34.CrossRefPubMed
7.
go back to reference Field TS, Gurwitz JH, Harrold LR, Rothschild J, DeBellis KR, Seger AC, et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc. 2004;52(8):1349–54.PubMedCrossRef Field TS, Gurwitz JH, Harrold LR, Rothschild J, DeBellis KR, Seger AC, et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc. 2004;52(8):1349–54.PubMedCrossRef
8.
go back to reference Frazier SC. Health outcomes and polypharmacy in elderly individuals: an integrated literature review. J Gerontol Nurs. 2005;31(9):4–11.PubMedCrossRef Frazier SC. Health outcomes and polypharmacy in elderly individuals: an integrated literature review. J Gerontol Nurs. 2005;31(9):4–11.PubMedCrossRef
9.
go back to reference Neutel CI, Perry S, Maxwell C. Medication use and risk of falls. Pharmacoepidemiol Drug Saf. 2002;11(2):97–104.PubMedCrossRef Neutel CI, Perry S, Maxwell C. Medication use and risk of falls. Pharmacoepidemiol Drug Saf. 2002;11(2):97–104.PubMedCrossRef
10.
go back to reference Cardwell K, Hughes CM, Ryan C. The association between anticholinergic medication burden and health related outcomes in the 'oldest old': a systematic review of the titerature. Drugs Aging. 2015;32(10):835–48.PubMedCrossRef Cardwell K, Hughes CM, Ryan C. The association between anticholinergic medication burden and health related outcomes in the 'oldest old': a systematic review of the titerature. Drugs Aging. 2015;32(10):835–48.PubMedCrossRef
11.
go back to reference Jamieson HA, Nishtala PS, Scrase R, Deely JM, Abey-Nesbit R, Hilmer SN, et al. Drug burden index and its association with hip fracture among older adults: a national population-based study. J Gerontol A Biol Sci Med Sci. 2019;74(7):1127–33.PubMedCrossRef Jamieson HA, Nishtala PS, Scrase R, Deely JM, Abey-Nesbit R, Hilmer SN, et al. Drug burden index and its association with hip fracture among older adults: a national population-based study. J Gerontol A Biol Sci Med Sci. 2019;74(7):1127–33.PubMedCrossRef
12.
go back to reference Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Cumming RG, Handelsman DJ, et al. High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther. 2012;91(3):521–8.PubMedCrossRef Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Cumming RG, Handelsman DJ, et al. High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther. 2012;91(3):521–8.PubMedCrossRef
13.
go back to reference Herr M, Robine J-M, Pinot J, Arvieu J-J, Ankri J. Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf. 2015;24(6):637–46.PubMedCrossRef Herr M, Robine J-M, Pinot J, Arvieu J-J, Ankri J. Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf. 2015;24(6):637–46.PubMedCrossRef
14.
go back to reference Yang F, Chen Q-W. Evaluation of frailty and influencing factors in old people in hospital institution. Med Baltim. 2018;97(3):e9634.CrossRef Yang F, Chen Q-W. Evaluation of frailty and influencing factors in old people in hospital institution. Med Baltim. 2018;97(3):e9634.CrossRef
15.
go back to reference Herr M, Sirven N, Grondin H, Pichetti S, Sermet C. Frailty, polypharmacy, and potentially inappropriate medications in old people: findings in a representative sample of the French population. Eur J Clin Pharmacol. 2017;73(9):1165–72.PubMedCrossRef Herr M, Sirven N, Grondin H, Pichetti S, Sermet C. Frailty, polypharmacy, and potentially inappropriate medications in old people: findings in a representative sample of the French population. Eur J Clin Pharmacol. 2017;73(9):1165–72.PubMedCrossRef
16.
go back to reference Pegorari MS, Tavares DM dos S. Factors associated with the frailty syndrome in elderly individuals living in the urban area. Rev Lat Am Enfermagem. 2014;22(5):874‑82. Pegorari MS, Tavares DM dos S. Factors associated with the frailty syndrome in elderly individuals living in the urban area. Rev Lat Am Enfermagem. 2014;22(5):874‑82.
17.
go back to reference Saum K-U, Schöttker B, Meid AD, Holleczek B, Haefeli WE, Hauer K, et al. Is polypharmacy associated with frailty in older people? results from the ESTHER cohort study. J Am Geriatr Soc. 2017;65(2):e27–32.PubMedCrossRef Saum K-U, Schöttker B, Meid AD, Holleczek B, Haefeli WE, Hauer K, et al. Is polypharmacy associated with frailty in older people? results from the ESTHER cohort study. J Am Geriatr Soc. 2017;65(2):e27–32.PubMedCrossRef
18.
go back to reference Jürschik P, Nunin C, Botigué T, Escobar MA, Lavedán A, Viladrosa M. Prevalence of frailty and factors associated with frailty in the elderly population of Lleida, Spain: the FRALLE survey. Arch Gerontol Geriatr. 2012;55(3):625–31.PubMedCrossRef Jürschik P, Nunin C, Botigué T, Escobar MA, Lavedán A, Viladrosa M. Prevalence of frailty and factors associated with frailty in the elderly population of Lleida, Spain: the FRALLE survey. Arch Gerontol Geriatr. 2012;55(3):625–31.PubMedCrossRef
19.
go back to reference Trevisan C, Veronese N, Maggi S, Baggio G, Toffanello ED, Zambon S, et al. Factors influencing transitions between frailty states in elderly adults: the progetto veneto anziani longitudinal study. J Am Geriatr Soc. 2017;65(1):179–84.PubMedCrossRef Trevisan C, Veronese N, Maggi S, Baggio G, Toffanello ED, Zambon S, et al. Factors influencing transitions between frailty states in elderly adults: the progetto veneto anziani longitudinal study. J Am Geriatr Soc. 2017;65(1):179–84.PubMedCrossRef
20.
go back to reference Jamsen KM, Bell JS, Hilmer SN, Kirkpatrick CMJ, Ilomäki J, Le Couteur D, et al. effects of changes in number of medications and drug burden index exposure on transitions between frailty states and death: the concord health and ageing in men project cohort study. J Am Geriatr Soc. 2016;64(1):89–95.PubMedCrossRef Jamsen KM, Bell JS, Hilmer SN, Kirkpatrick CMJ, Ilomäki J, Le Couteur D, et al. effects of changes in number of medications and drug burden index exposure on transitions between frailty states and death: the concord health and ageing in men project cohort study. J Am Geriatr Soc. 2016;64(1):89–95.PubMedCrossRef
22.
go back to reference Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781–7.CrossRefPubMed Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781–7.CrossRefPubMed
23.
go back to reference Faure R, Dauphinot V, Krolak-Salmon P, Mouchoux C. A standard international version of the drug burden Index for cross-national comparison of the functional burden of medications in older people. J Am Geriatr Soc. 2013;61(7):1227–8.PubMedCrossRef Faure R, Dauphinot V, Krolak-Salmon P, Mouchoux C. A standard international version of the drug burden Index for cross-national comparison of the functional burden of medications in older people. J Am Geriatr Soc. 2013;61(7):1227–8.PubMedCrossRef
24.
go back to reference Durán CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol. 2013;69(7):1485–96.PubMedCrossRef Durán CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol. 2013;69(7):1485–96.PubMedCrossRef
25.
go back to reference Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;15:31.PubMedPubMedCentralCrossRef Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;15:31.PubMedPubMedCentralCrossRef
26.
go back to reference Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(21):11–4.PubMed Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(21):11–4.PubMed
27.
go back to reference Folstein MF, Folstein SE, McHugh PR. « Mini-mental state ». A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189‑98. Folstein MF, Folstein SE, McHugh PR. « Mini-mental state ». A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189‑98.
28.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.PubMedCrossRef
29.
go back to reference Gutiérrez-Valencia M, Izquierdo M, Cesari M, Casas-Herrero Á, Inzitari M, Martínez-Velilla N. The relationship between frailty and polypharmacy in older people: a systematic review. Br J Clin Pharmacol. 2018;84(7):1432–44.PubMedPubMedCentralCrossRef Gutiérrez-Valencia M, Izquierdo M, Cesari M, Casas-Herrero Á, Inzitari M, Martínez-Velilla N. The relationship between frailty and polypharmacy in older people: a systematic review. Br J Clin Pharmacol. 2018;84(7):1432–44.PubMedPubMedCentralCrossRef
30.
go back to reference Kouladjian L, Gnjidic D, Chen T, Hilmer S, Mangoni A. Drug burden index in older adults: theoretical and practical issues. Clin Interv Aging. 2014;1503. Kouladjian L, Gnjidic D, Chen T, Hilmer S, Mangoni A. Drug burden index in older adults: theoretical and practical issues. Clin Interv Aging. 2014;1503.
31.
go back to reference Santos-Eggimann B, Cuénoud P, Spagnoli J, Junod J. Prevalence of frailty in middle-aged and older community-dwelling Europeans living in 10 countries. J Gerontol A Biol Sci Med Sci. 2009;64(6):675–81.PubMedCrossRef Santos-Eggimann B, Cuénoud P, Spagnoli J, Junod J. Prevalence of frailty in middle-aged and older community-dwelling Europeans living in 10 countries. J Gerontol A Biol Sci Med Sci. 2009;64(6):675–81.PubMedCrossRef
32.
go back to reference Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc. 2012;60(8):1487–92.PubMedCrossRef Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc. 2012;60(8):1487–92.PubMedCrossRef
33.
go back to reference Szewieczek J, Bieniek J, Wilczyński K. Fried frailty phenotype assessment components as applied to geriatric inpatients. Clin Interv Aging. 2016;453. Szewieczek J, Bieniek J, Wilczyński K. Fried frailty phenotype assessment components as applied to geriatric inpatients. Clin Interv Aging. 2016;453.
34.
go back to reference Frost R, Belk C, Jovicic A, Ricciardi F, Kharicha K, Gardner B, et al. Health promotion interventions for community-dwelling older people with mild or pre-frailty: a systematic review and meta-analysis. BMC Geriatr. 2017;17(1):157.PubMedPubMedCentralCrossRef Frost R, Belk C, Jovicic A, Ricciardi F, Kharicha K, Gardner B, et al. Health promotion interventions for community-dwelling older people with mild or pre-frailty: a systematic review and meta-analysis. BMC Geriatr. 2017;17(1):157.PubMedPubMedCentralCrossRef
35.
go back to reference Puts MTE, Toubasi S, Andrew MK, Ashe MC, Ploeg J, Atkinson E, et al. Interventions to prevent or reduce the level of frailty in community-dwelling older adults: a scoping review of the literature and international policies. Age Ageing. 2017;46(3):383–92.PubMedPubMedCentral Puts MTE, Toubasi S, Andrew MK, Ashe MC, Ploeg J, Atkinson E, et al. Interventions to prevent or reduce the level of frailty in community-dwelling older adults: a scoping review of the literature and international policies. Age Ageing. 2017;46(3):383–92.PubMedPubMedCentral
Metadata
Title
Medication exposure and frailty in older community-dwelling patients: a cross-sectional study
Authors
Elsa Reallon
Bénédicte Chavent
Frédéric Gervais
Virginie Dauphinot
Julien Vernaudon
Pierre Krolak-Salmon
Christelle Mouchoux
Teddy Novais
Publication date
01-04-2020
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 2/2020
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01007-2

Other articles of this Issue 2/2020

International Journal of Clinical Pharmacy 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.